Bayer has no plans to spin off its Monsanto subsidiary despite an unrelenting wave of mass tort litigation over its Roundup weedkiller. Rumors of a structural breakup had circulated as the German conglomerate struggled under the weight of roughly 100,000 plaintiffs. As first reported by Reuters, a company representative clarified that while corporate restructuring remains a viable legal alternative for the future, management is exclusively focused on operational performance and active defense of its current docket.
The stakes extend far beyond the courtroom, threatening the domestic supply chain for agricultural chemicals. On stage at The Wall Street Journal's Global Food Forum, Bayer Chief Executive Officer Bill Anderson warned that the litigation directly compromises the company's manufacturing pipeline. Anderson stated that "if there's not a solution to the litigation problem on glyphosate, there won't be American-produced glyphosate." Currently, Bayer operates as the sole manufacturer of the pesticide inside the United States, forcing the domestic agricultural sector to rely on generic imports from China if domestic production halts.
To clear its balance sheet of the systemic liability, the company has proposed a $7.25 billion global class action settlement designed to conclude the vast majority of pending Roundup lawsuits. However, the upcoming transition out of litigation remains stalled as several prominent plaintiffs have filed formal objections to the terms of the deal. Management intends to maintain its corporate structure while these regulatory and courtroom battles play out.
